March 2016 Newsletter
Overall market growth rates were roughly in line with expectations, with the exception of refractive procedures, which declined.
AIOS produces an engrossing and successful conference despite historic rain.
Lack of funding, great unmet need force ophthalmologists to make the most of what they have.
Many Indians expect doctors to overcharge and do unneeded tests.
Corporate medicine and investment in public and charity hospitals are putting pressure on solo and family practices.
Health officials banned ophthalmic use of the drug in January after 15 patients lost sight following an injection.
The firm’s market cap has dropped from $90 billion to $11.5 billion; CEO Pearson appears committed to keeping Bausch + Lomb.
US FDA approval of Transcend’s CyPass is expected in late 2016 or early 2017.
The commander said his vision declined early in the trip and then leveled off.
The new draft document increases requirements for showing bioequivalence.
The segment is the largest in retinal diagnostic market.
Country is home to one-third of the world’s blind; retinal products are the largest ophthalmic revenue segment.
The disposable contact lens is designed to provide a 24-hour recording of changes in the shape of the eye, which correlate with IOP fluctuations.
The research is a follow-up to The Ocular Hypertension Treatment Study led by the same Washington University researchers in the 1990s.
In one study, scientists successfully created a functional lens in the eyes of a dozen Chinese infants suffering from congenital cataracts.
